IMPACT Therapeutics licenses Senaparib to Pharmanovia
August 03, 2026 | 15:30
IMPACT Therapeutics, listed under stock code 07630.HK, signed an exclusive license agreement with Pharmanovia for Senaparib across Europe, the Middle East, North Africa, Australia and New Zealand.
Mobile Version